Ipamorelin half life: how long it actually lasts

Last updated 2026-07-25

What is ipamorelin's half life in humans?

The core pharmacokinetic data on ipamorelin in people comes from a 1999 study that modeled plasma concentration and growth hormone response after dosing in human volunteers. That paper, published in Pharmaceutical Research, built a pharmacokinetic-pharmacodynamic model and reported a half life in the range of about 2 hours for ipamorelin in humans ^[1]. That's the number nearly every dosing conversation about ipamorelin traces back to, whether people cite it correctly or not. Two hours is short. For comparison, that's faster clearance than many longer acting GH secretagogues and growth hormone releasing hormone analogs used alongside it. A 2 hour half life means the drug is mostly gone from circulation within 8 to 10 hours (roughly 4 to 5 half lives), but the practical window that matters for GH pulsing is much shorter than that, because the receptor interaction and downstream GH release happen fast and then fade. It's worth being honest about the limits of this data point. The 1999 study is over 25 years old, ran in a small volunteer cohort, and used the analytic methods available at the time. Nobody has published a large modern human PK study that revisits this number with current mass spectrometry standards. So "2 hours" is the best available answer, not a settled constant measured a dozen times across populations.

How was the half life actually measured?

The 1999 Pharmaceutical Research study used a pharmacokinetic-pharmacodynamic (PK-PD) modeling approach: researchers gave ipamorelin to human volunteers, drew blood over time to track plasma concentration, and simultaneously tracked the growth hormone response curve, then fit a model connecting the two ^[1]. This is standard practice for peptide hormones where the thing you actually care about (GH release) doesn't map linearly onto blood concentration of the drug itself. Separately, metabolism and degradation work has looked at what actually happens to ipamorelin once it's in the body. A 2012 analytical chemistry paper examined the metabolism of growth hormone releasing peptides, including how they get broken down enzymatically ^[2]. And a 2015 Drug Testing and Analysis paper specifically tracked ipamorelin metabolites in human urine after nasal administration, alongside GHRP-1, GHRP-2, GHRP-6, and hexarelin, which is part of why anti-doping labs can detect these compounds well after the parent molecule has cleared ^[3]. That urine metabolite work matters for a different reason than dosing: it tells you the drug leaves a trace long after the 2 hour plasma half life would suggest, because metabolites persist and get concentrated in urine. Half life in blood and detectability in a doping test are not the same question, and people conflate them constantly.

Why does ipamorelin's short half life matter for dosing frequency?

A short half life means the drug doesn't hang around to keep stimulating the pituitary. Growth hormone secretagogues work by triggering a pulse of GH release, and that pulse only lasts as long as there's enough drug at the receptor to keep the signal going. With a roughly 2 hour clearance, a single dose gives you one usable pulse window, not an all day effect. This is the physiological reason most protocols call for dosing once or twice a day rather than a single weekly injection. If you want another GH pulse later in the day, you need another dose, because the first one is functionally gone. This isn't bodybuilding folklore, it follows directly from the clearance kinetics the 1999 study described ^[1]. It's also why timing relative to meals and sleep gets so much attention in practical protocols. GH secretagogue activity is blunted by circulating glucose and insulin, so dosing on an empty stomach (and often right before bed, when natural GH pulses already cluster) is meant to line up the drug's short active window with a moment when the body is primed to respond. For the mechanics of that timing, see ipamorelin dosage and ipamorelin timeline: what to expect.

How does ipamorelin's half life compare to other GH secretagogues?

Ipamorelin is often paired with tesamorelin or CJC-1295 precisely because their kinetics are different. Tesamorelin and CJC-1295 (particularly the DAC-conjugated version) are built to last longer in circulation, extending GHRH signaling over a longer window, while ipamorelin's short half life gives you a sharp, selective pulse on the ghrelin receptor side (GHS-R1a) without much drift into cortisol or prolactin release, a selectivity point that goes back to the original 1998 European Journal of Endocrinology paper naming ipamorelin "the first selective growth hormone secretagogue" ^[4]. Here's a rough comparison of how these compounds are generally described in the pharmacology literature, though direct head to head human half life comparisons in a single study are limited:

Does a short half life mean ipamorelin is less effective?

No. Short half life is not the same as low potency or low relevance. Ipamorelin's defining feature in the original 1998 characterization was selectivity, not duration: it stimulates GH release through the ghrelin receptor without meaningfully triggering ACTH, cortisol, or prolactin release the way some older secretagogues (like GHRP-6) can ^[4]. That selectivity is arguably more clinically important than a longer half life would be, because it means fewer off target hormonal effects per dose. Animal work backs up that the pulse itself, even though brief, produces measurable downstream effects. A 1999 study found ipamorelin induced longitudinal bone growth in rats ^[5], and a 2000 study in The Journal of Endocrinology found ipamorelin (and GHRP-6) increased bone mineral content in adult female rats ^[6]. Separately, ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats in a 2001 study ^[7]. None of these effects required the drug to linger in circulation; they required repeated pulsatile exposure, which is exactly what a short half life plus repeat dosing is designed to produce. A 2002 histopathology study also looked at what happens with chronic treatment: young female rats given ipamorelin over time showed a measurable somatotroph (GH-producing cell) response when tested in vitro afterward, suggesting the pituitary's GH-secreting cells adapt to repeated pulsed stimulation rather than simply desensitizing ^[8].

What happens if you miss a dose or space doses out further?

Because ipamorelin clears in roughly 2 hours, missing a single dose doesn't create a withdrawal effect or a rebound problem the way stopping some longer half life hormone therapies might. You simply miss that pulse window. The next scheduled dose picks back up the same pulsatile pattern. There's no published human data on optimal dosing interval spacing beyond the general pattern used in the studies available (once or twice daily). Nobody has run a rigorous trial comparing, say, every-other-day dosing against daily dosing for ipamorelin specifically in humans at the doses commonly used off label. That's a real gap, and it means most practical spacing advice is extrapolated from the half life number and general endocrinology principles about pulsatile GH release, not from a dedicated dose-interval trial. If you're building out an actual schedule, the practical dosing mechanics (injection site rotation, timing relative to food, how to draw up a dose) matter more day to day than the theoretical half life. See ipamorelin how to inject and ipamorelin injection sites for that side of it.

Does the half life change with nasal or other administration routes?

Yes, route of administration changes the absorption profile even if the underlying elimination half life of the molecule itself is similar. A 1998 Xenobiotica paper specifically evaluated the pharmacokinetics of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption, comparing that route to injection ^[9]. Nasal delivery of peptides generally has lower and more variable bioavailability than subcutaneous injection, because peptides are large and get degraded or poorly absorbed across mucosal membranes. This matters practically because most current use of ipamorelin (in the clinical and compounding context) is via subcutaneous injection, not nasal spray, and the human PK modeling paper that established the ~2 hour half life number used injected dosing ^[1]. If you see half life or dosing claims tied to nasal ipamorelin, treat those as a different pharmacokinetic scenario, not interchangeable with injection-based numbers.

Is there stability or storage data related to how ipamorelin behaves in solution versus in the body?

Half life in the body (a pharmacokinetic property) is a completely different question from shelf stability of the reconstituted peptide in a vial (a chemistry and storage question). People sometimes conflate the two. The plasma half life of about 2 hours ^[1] tells you nothing about how long a reconstituted vial stays potent in a refrigerator. There isn't a peer-reviewed human study in this research pack that specifically measures ipamorelin degradation kinetics in stored solution over weeks, so general peptide storage guidance (refrigerate after reconstitution, avoid repeated freeze-thaw, protect from light) applies here based on standard peptide chemistry practice rather than a dedicated ipamorelin stability trial. For the practical storage question, see does ipamorelin need to be refrigerated.

Why do forum sources give wildly different half life numbers?

A lot of the half life claims floating around bodybuilding and forum content are not sourced to the actual 1999 PK modeling paper at all. Some numbers get borrowed from other secretagogues, some are just repeated from site to site without a citation, and some conflate detection window (how long metabolites show up in a urine test) with elimination half life (how long the parent drug circulates in plasma). Those are genuinely different numbers. The 2015 Drug Testing and Analysis paper on ipamorelin metabolites in human urine after nasal administration exists specifically because anti-doping testing needs to know how long traces are detectable, which is a longer window than the roughly 2 hour plasma half life ^[3]. A 2018 Growth Hormone & IGF Research paper analyzing black market growth-promoting products found inconsistent labeling and composition issues in unregulated products, which is a separate but related reason to be skeptical of unsourced dosing and pharmacokinetic claims circulating outside peer-reviewed literature ^[10]. If a source doesn't cite the original PK study or a peer-reviewed follow-up, treat the number as folklore, not fact.

Does the half life differ in people with different body compositions or hormonal states?

There's no published human data in the peer-reviewed literature specifically breaking down ipamorelin half life by body composition, sex, or hormonal status. The 1999 PK-PD study established the baseline number in its volunteer cohort, but subgroup analysis of that kind hasn't been published ^[1]. Related but distinct work has looked at how GH secretagogues affect body composition and hormonal context rather than how those factors change the drug's clearance. A 2020 Translational Andrology and Urology paper reviewed the role of growth hormone secretagogues in managing body composition in hypogonadal males, discussing secretagogues as a category rather than measuring pharmacokinetic differences by hormonal state ^[11]. Separately, a 2001 Biochemical and Biophysical Research Communications paper found GH secretagogues can stimulate adiposity through a GH-independent mechanism ^[12], which is a mechanism question, not a clearance-rate question. So the honest answer here is: we don't know if half life meaningfully differs by body composition in humans, because nobody has published that specific comparison.

What is ipamorelin's regulatory and sourcing status, and how does that connect to dosing?

Ipamorelin is not an FDA-approved drug on its own; you won't find it in the Drugs@FDA database of approved products ^[13]. It's available through compounding pharmacies, most commonly as part of a tesamorelin/ipamorelin blend rather than as a standalone product. Bulk drug substances used in 503A compounding are governed by 21 CFR 216.23 and the associated statute at 21 U.S.C. 353a ^[14][15], with FDA maintaining lists of substances nominated and evaluated for compounding use ^[16]. This regulatory context matters for the half life conversation because it means there's no FDA-reviewed label with an authoritative pharmacokinetic section the way there would be for an approved drug. Everything cited in this article comes from the peer-reviewed pharmacology literature, not from a package insert, because there isn't one. Ipamorelin Co works with providers who source through this compounding pathway and dispense ipamorelin as part of a tesamorelin/ipamorelin blend reviewed by a prescribing provider, not as a standalone product, which is the current regulatory reality for this peptide. A 2026 Journal of the American Academy of Orthopaedic Surgeons review on therapeutic peptides in orthopaedics discusses this broader compounding and evidence landscape for peptides used in musculoskeletal contexts ^[17], and a companion 2026 American Journal of Sports Medicine primer covers injectable peptide therapy for sports medicine physicians more generally ^[18], both underscoring that clinical use of compounded peptides currently runs ahead of large controlled human trials for many specific pharmacokinetic questions, including finer detail on ipamorelin's half life.

Frequently asked questions

What is the half life of ipamorelin in humans?

The main human pharmacokinetic data, from a 1999 Pharmaceutical Research modeling study, puts ipamorelin's half life at approximately 2 hours after administration in volunteers. That short clearance time is why dosing protocols use repeated small doses rather than one large infrequent dose, to create repeated GH pulses rather than one sustained exposure.

Does ipamorelin's short half life mean you need to inject more often?

Yes, in practice. Because the drug clears in roughly 2 hours, a single dose only produces one GH pulse window. Most protocols call for once or twice daily dosing to generate multiple pulses across the day, typically timed around fasting states and before sleep rather than at a fixed clock interval.

Is ipamorelin's half life shorter than CJC-1295's?

Generally yes. Ipamorelin's plasma half life is roughly 2 hours based on the 1999 human PK study, while CJC-1295 formulated with DAC is specifically engineered to bind albumin and persist for days, which is why the two are often dosed on very different schedules within the same blend.

Can you detect ipamorelin in a urine test long after its half life has passed?

Yes. A 2015 Drug Testing and Analysis study tracked ipamorelin metabolites in human urine after nasal administration and found detectable traces persist well beyond the roughly 2 hour plasma half life, because metabolites accumulate and clear more slowly through urine than the parent compound clears from blood.

Does a longer half life mean a growth hormone secretagogue works better?

Not necessarily. Ipamorelin's defining advantage documented in its original 1998 characterization is receptor selectivity, meaning it triggers GH release without significantly raising cortisol or prolactin, not duration of action. A short half life paired with repeat dosing can still produce meaningful downstream effects like measurable bone mineral changes in animal studies.

How was ipamorelin's half life actually measured?

Researchers in the 1999 Pharmaceutical Research study gave ipamorelin to human volunteers, sampled blood over time, and built a pharmacokinetic-pharmacodynamic model connecting plasma concentration to the growth hormone response curve. That model produced the roughly 2 hour half life figure most cited today.

Does nasal administration change ipamorelin's half life?

Route of administration changes absorption and bioavailability more than it changes the molecule's underlying elimination rate. A 1998 Xenobiotica study specifically evaluated nasal absorption of ipamorelin and found it behaves differently from injection in terms of uptake, so half life figures from injected dosing shouldn't be assumed to transfer directly to nasal use.

Is there an FDA-approved ipamorelin product with an official half life listed on a label?

No. Ipamorelin doesn't appear in the FDA's Drugs@FDA database of approved products, so there's no FDA-reviewed label with an authoritative pharmacokinetics section. It's available through compounding pharmacies, generally as part of a tesamorelin/ipamorelin blend, under the 503A compounding framework rather than as an approved standalone drug.

Does body composition or age change how fast ipamorelin clears from the body?

There's no published human study breaking down ipamorelin's half life by body composition, sex, or age. The original 1999 PK modeling study established a baseline figure in its volunteer cohort but didn't stratify by these factors, so this remains an open question in the literature rather than a settled answer.

Why do some websites list a much longer or shorter ipamorelin half life than 2 hours?

Many of those figures aren't sourced to the actual 1999 pharmacokinetic study at all. Some conflate detection window in urine testing with plasma half life, others borrow numbers from different secretagogues entirely. If a claim doesn't cite a specific peer-reviewed source, treat it as unverified rather than established pharmacology.

Does missing a dose of ipamorelin cause any rebound or withdrawal effect?

There's no evidence of a withdrawal effect from missing a dose, largely because the roughly 2 hour half life means the drug is already mostly cleared between scheduled doses under normal use. Missing a dose simply means missing that pulse window rather than creating any drug accumulation or dependency issue documented in the literature.

Why is ipamorelin often paired with a longer-acting compound like tesamorelin instead of used alone?

The short half life gives a sharp, selective GH pulse through the ghrelin receptor, while a longer-acting GHRH analog like tesamorelin sustains a separate signaling pathway over a longer window. Pairing the two, which is how ipamorelin is currently dispensed as a blend, is meant to combine a sustained signal with periodic pulses rather than relying on one mechanism alone.

Sources

1. Raun et al., Pharmaceutical Research, 1999 (PMID 10496658): Human PK-PD modeling study establishing ipamorelin's plasma half life at approximately 2 hours in volunteers
2. Analytical Chemistry, 2012 (PMID 23101768): Metabolism study of growth hormone releasing peptides describing enzymatic breakdown pathways
3. Drug Testing and Analysis, 2015 (PMID 25869809): Ipamorelin metabolites detectable in human urine after nasal administration, distinct from plasma half life
4. European Journal of Endocrinology, 1998 (PMID 9849822): Original characterization of ipamorelin as the first selective growth hormone secretagogue, without significant cortisol/prolactin effects
5. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats despite short circulating half life
6. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
7. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decrease in bone formation in adult rats
8. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment produced a measurable somatotroph response in vitro in young female rats
9. Xenobiotica, 1998 (PMID 9879640): Pharmacokinetic evaluation of ipamorelin with emphasis on nasal absorption versus other routes
10. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found labeling and composition inconsistencies
11. Translational Andrology and Urology, 2020 (PMID 32257855): Review of growth hormone secretagogues for body composition management in hypogonadal males
12. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through a GH-independent mechanism
13. FDA, Drugs@FDA database: Ipamorelin is not listed as an FDA-approved drug product
14. 21 CFR 216.23, 503A Bulks List: Regulatory framework governing bulk drug substances used in 503A pharmacy compounding
15. 21 U.S.C. 353a, pharmacy compounding statute: Statutory basis for pharmacy compounding under section 503A
16. FDA, bulk drug substances nominated for use in compounding: FDA maintains a current list of bulk substances nominated and evaluated for compounding use
17. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics discussing compounding and evidence landscape
18. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for sports medicine physicians on injectable peptide therapy covering clinical use context